Published in Clin Pharmacol on August 09, 2013
Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis. PLoS One (2014) 0.84
An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res (2014) 0.83
The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. PLoS One (2015) 0.80
Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer (2014) 0.80
Evaluation of Selected Immunomodulatory Glycoproteins as an Adjunct to Cancer Immunotherapy. PLoS One (2016) 0.75
Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity. Clin Pharmacol (2013) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother (2009) 3.62
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A (1997) 2.53
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol (2010) 2.51
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs (2010) 2.09
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A (1999) 1.61
Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol (2010) 1.47
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine (2004) 1.25
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol (1989) 1.04
Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med (2008) 1.85
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2006) 0.97
Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol (2009) 0.91
An unusual BRCA mutation distribution in a high risk cancer genetics clinic. Fam Cancer (2013) 0.79
Whole-brain radiation therapy in melanoma: an open question. Lancet Oncol (2010) 0.78